Avatrombopag maleate
Product Specifications
CAS Number
677007-74-8
Target
STAT|||ERK|||Cytochromes P450|||Others|||Thrombopoietin Receptor
Related Pathways
JAK/STAT signaling|||Metabolism|||Stem Cells|||MAPK|||Others|||Immunology/Inflammation
Bioactivity
Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.
Smiles
OC(=O)\C=C/C(O)=O.OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1
Molecular Formula
C33H38Cl2N6O7S2
Molecular Weight
765.72
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
124176-ML405 100 µL
CA1 (Carbonic Anhydrase 1, Carbonic Anhydrase I, CA-I, Carbonate Dehydratase I, Carbonic Anhydrase B, CAB) (MaxLight 405) discontinued
Ask
View Details